Trial Assigning Individualized Options for Treatment (TAILORx)
Source: View publication →
The TAILORx trial demonstrated that for women with early-stage, HR-positive, HER2-negative, axillary lymph node-negative breast cancer and an intermediate Oncotype DX recurrence score (11-25), adjuvant endocrine therapy alone is non-inferior to chemoendocrine therapy in terms of invasive disease-free survival.
Key Findings
Study Design
Study Limitations
Clinical Significance
The TAILORx trial provides definitive evidence that allows clinicians to safely omit adjuvant chemotherapy for the vast majority of women with HR-positive, HER2-negative, node-negative breast cancer who have an intermediate Oncotype DX recurrence score, thereby sparing them from unnecessary treatment toxicity and healthcare costs.
Historical Context
Prior to TAILORx, clinical uncertainty persisted regarding whether intermediate-risk patients (as defined by the Oncotype DX assay) derived sufficient benefit from chemotherapy to justify its use. This trial was established to prospectively validate the utility of the 21-gene expression assay and standardize clinical decision-making for a significant segment of breast cancer patients.
Guided Discussion
High-yield insights from every perspective
What is the biological rationale for using the 21-gene recurrence score (Oncotype DX) to decide on chemotherapy in HR-positive, HER2-negative breast cancer, and which specific biological pathways are most influential in determining a 'low' versus 'high' score?
Key Response
HR-positive breast cancer is primarily driven by estrogen receptor signaling. The 21-gene assay measures the expression of genes related to proliferation (like Ki-67), estrogen signaling, and HER2. A high score indicates a highly proliferative, less 'luminal-like' tumor that is more likely to be sensitive to DNA-damaging chemotherapy, whereas a low score suggests a tumor that is primarily driven by hormone pathways and can be managed with endocrine therapy alone.
A 58-year-old postmenopausal woman presents with a 1.5 cm, Grade 2, ER/PR-positive, HER2-negative, node-negative invasive ductal carcinoma. Her Oncotype DX Recurrence Score is 22. Based on the TAILORx results, what is the most appropriate adjuvant management, and what is the expected 9-year rate of distant recurrence for this patient?
Key Response
According to TAILORx, postmenopausal women with an intermediate recurrence score (11–25) derive no significant benefit from the addition of chemotherapy to endocrine therapy. The trial demonstrated that endocrine therapy alone is non-inferior to chemoendocrine therapy in this group. For patients with a score of 11–25, the distant recurrence rate at 9 years was approximately 3%, regardless of whether they received chemotherapy or not.
TAILORx identified an interaction between age and treatment effect for women aged 50 or younger with a recurrence score of 16–25. Analyze the potential mechanisms for why chemotherapy appeared to provide a small benefit in this subgroup and discuss how this affects the choice between chemotherapy and ovarian function suppression (OFS).
Key Response
In women ≤50 with an RS of 16–25, chemotherapy reduced distant recurrence by ~1.6% (for RS 16-20) to ~6.5% (for RS 21-25). It is unclear if this is due to chemotherapy's cytotoxic effect or its ability to induce premature ovarian failure (chemical oophorectomy). Since most TAILORx participants did not receive OFS, many experts argue that for these young patients, intensified endocrine therapy (Aromatase Inhibitor + OFS) might provide a similar risk reduction to chemotherapy, offering a management alternative.
As an attending, how do you integrate the findings of the TAILORx 'clinical-genomic' risk analysis into your practice for a patient who has a 'high' clinical risk (e.g., T2, Grade 3) but an 'intermediate' genomic score (RS 11-25)?
Key Response
Secondary analyses of TAILORx data showed that clinical risk (tumor size and grade) provides prognostic information independent of the recurrence score. While the RS remains the primary predictor of chemotherapy benefit, a high clinical risk identifies patients with a higher absolute risk of recurrence. In younger women with RS 16-25, high clinical risk may sway the recommendation toward chemotherapy or more aggressive endocrine blockade, whereas in older women, ET alone remains the standard due to the lack of relative benefit from chemotherapy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TAILORx trial utilized a non-inferiority design with a hazard ratio (HR) margin of 1.322 for the primary endpoint of invasive disease-free survival (IDFS). Critique the selection of this margin and the use of IDFS as an endpoint for a disease where the majority of deaths are non-breast cancer related and recurrences often occur after the 10-year mark.
Key Response
The HR margin of 1.322 was chosen to ensure that the absolute difference in 5-year IDFS would not exceed 3%. However, in a low-risk population with excellent survival, a large relative hazard can represent a very small absolute difference, potentially leading to 'non-inferiority' that masks clinically relevant differences. Furthermore, IDFS includes local recurrences and second primary cancers; in HR+ disease, 'distant recurrence-free survival' (DRFS) is often considered a more 'pure' measure of chemotherapy efficacy, especially since late distant recurrences are a hallmark of this subtype.
If you were the primary reviewer for the TAILORx manuscript, how would you address the potential for 'immortal time bias' or 'selection bias' regarding the exclusion of the very-low (0-10) and very-high (26+) score cohorts from the primary non-inferiority randomization?
Key Response
A reviewer would note that excluding the extremes of the RS range effectively 'pre-filters' the population to the group with the most uncertainty, which is the study's strength. However, the editor would flag that the overall generalizability of the findings depends on the precision of these cutoffs. The reviewer would demand a rigorous sensitivity analysis to ensure that the 11 and 25 thresholds—originally defined somewhat arbitrarily—actually represent biological transition points where chemotherapy benefit begins to emerge.
TAILORx led to a significant shift in NCCN and ASCO guidelines regarding the RS thresholds. How do the TAILORx cutoffs (11-25) compare to the original 21-gene assay validation study cutoffs (18-30), and what is the specific Level of Evidence (LOE) now assigned to the omission of chemotherapy in N0 postmenopausal patients with an RS of 20?
Key Response
The original NSABP B-20 study used cutoffs of <18 (low), 18-30 (intermediate), and >31 (high). TAILORx prospectively redefined the intermediate range as 11-25 to minimize the risk of under-treating potentially high-risk patients. Current NCCN guidelines (v1.2024) assign a Category 1 (Level of Evidence 1A) recommendation for endocrine therapy alone in postmenopausal, node-negative patients with an RS <26, directly based on the definitive prospective evidence provided by TAILORx.
Clinical Landscape
Noteworthy Related Trials
NSABP B-14 Trial
Tested
Tamoxifen therapy
Population
Node-negative, estrogen-receptor-positive breast cancer
Comparator
Placebo
Endpoint
Disease-free survival
SOFT Trial
Tested
Ovarian function suppression plus tamoxifen or exemestane
Population
Premenopausal women with hormone-receptor-positive early breast cancer
Comparator
Tamoxifen alone
Endpoint
Disease-free survival
MINDACT Trial
Tested
70-gene signature assay (MammaPrint) guided chemotherapy
Population
Early-stage breast cancer with clinical and genomic risk discordance
Comparator
Standard clinical risk assessment
Endpoint
Distant metastasis-free survival at 5 years
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis